{"DataElement":{"publicId":"2426058","version":"1","preferredName":"Hormone Refractory Prostate Carcinoma Other Diagnosis Specify","preferredDefinition":"the free-text field to specify other method of diagnosis of hormone refractory prostate cancer.","longName":"HOR_R_PR_O_DX_SPEC","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2425593","version":"1","preferredName":"Hormone Refractory Prostate Carcinoma Other Diagnosis","preferredDefinition":"information related to the other method of diagnosis of hormone refractory, not responding to treatment, prostate cancer.","longName":"HOR_REFR_PRST_O_DX","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2425590","version":"1","preferredName":"Hormone Refractory Prostate Carcinoma","preferredDefinition":"Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various endocrine glands and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects.:Refractory; not responding to treatment.:Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","longName":"C2315:C38014:C4863","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone","conceptCode":"C2315","definition":"Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various endocrine glands and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Refractory","conceptCode":"C38014","definition":"Not responding to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"049B5946-27C4-2FE1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-11-02","modifiedBy":"ONEDATA","dateModified":"2005-11-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2425591","version":"1","preferredName":"Other Diagnosis","preferredDefinition":"Not otherwise specified.:The process of identifying a disease by the signs and symptoms.","longName":"C17649:C15220","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"049B5946-27C8-2FE1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-11-02","modifiedBy":"ONEDATA","dateModified":"2005-11-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"049B5946-27C9-2FE1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-11-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018786","version":"1","preferredName":"Disease Response Specify","preferredDefinition":"the free-text field to specify an aspect of disease response.","longName":"DZ_RESP_SPEC","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184338","version":"1","preferredName":"Specify","preferredDefinition":"Specify; be specific about something; define clearly.","longName":"Specify","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-2084-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8A14E97-9CFE-5BE2-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-03-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-03-11","modifiedBy":"CAMPBELB","dateModified":"2005-07-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811910","version":"1","longName":"Prostate","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CRF Text","type":"Preferred Question Text","description":"Other, specify","url":null,"context":"CTEP"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"04AA6F30-17C7-3F42-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-11-03","modifiedBy":"CAMPBELB","dateModified":"2008-04-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}